Sales and Marketing
Urgent need to address mental health crisis among kidney patients
February 28, 2022 Sales and Marketing
Kidney Research UK has released their findings from a survey of 1,000 kidney disease patients in the UK, revealing the …
Kapruvia receives positive CHMP opinion for pruritus in hemodialysis patients
February 28, 2022 Sales and Marketing
The CHMP has approved Kapruvia (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients. …
CanSinoBIO’s Convidecia approved as heterologous COVID-19 booster in China
February 21, 2022 Sales and Marketing
CanSino Biologics announced that its recombinant novel coronavirus vaccine has been approved by the Joint Prevention and Control Mechanism of …
FDA approval of first disease-modifying drug for treatment of rare lifelong anaemia
February 21, 2022 Sales and Marketing
Agios Pharmaceuticals has announced the FDA approval of Pyrukynd (mitapivat), for the treatment of haemolytic anaemia in adults with pyruvate …
‘Historic’ results for breast cancer drug and promise for broader use
February 21, 2022 Sales and Marketing
AstraZeneca has shared that its drug, Enhertu, has demonstrated meaningful survival improvements in patients with breast cancer, compared with physician’s …
FDA considers approving second COVID-19 booster jab
February 21, 2022 Sales and Marketing
US health regulators are looking at authorising a potential fourth dose of a COVID-19 vaccine, as reported by the Wall …
FDA approves Eversense CGM system for use for up to six months
February 14, 2022 Sales and Marketing
The FDA has approved Senseonics’ Eversense E3 CGM System, which includes proprietary sacrificial boronic acid (SBA) technology to extent longevity …
AbbVie submits applications for treatment of chronic disease
February 14, 2022 Sales and Marketing
AbbVie has announced the submission of applications seeking the approval of upadacitinib, (RINVOQ®, 15 mg once daily) for the treatment …
Gilead’s HIV treatment demonstrates high efficacy and viral suppression at five years
February 14, 2022 Sales and Marketing
Gilead Sciences has announced the presentation of cumulative five-year results from two Phase III studies of Biktarvy. The new, long-term …
First UK Lassa fever death in over a decade
February 14, 2022 Sales and Marketing
A patient in Bedfordshire has died from a confirmed case of Lassa fever, the UK Health Security Agency (UKHSA) has …
First gene therapy for rare genetic neurodegenerative disorder in children
February 7, 2022 Sales and Marketing
NICE has published a draft highly specialised technologies guidance, recommending gene therapy atidarsagene autotemcel for some children with the rare, …
NICE approves new treatment for chronic heart failure
February 7, 2022 Sales and Marketing
Empagliflozin (Jardiance®) has received a positive NICE recommendation for the treatment of chronic heart failure. NICE has announced that empagliflozin …
FDA approves Vabysmo to treat vision-threatening retinal conditions
January 31, 2022 Sales and Marketing
The FDA has approved vabysmo (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration and diabetic macular edema. …
Almirall announces licensing agreement to accelerate antibody drug discovery
January 31, 2022 Sales and Marketing
Almirall has announced a multi-target licensing agreement with Ablexis, focussed on licensing its AlivaMab Mouse technology, and a research collaboration …
Positive CHMP opinion for treatment of rare unpredictable disease
January 31, 2022 Sales and Marketing
Blueprint Medicines has announced that the CHMP has adopted a positive opinion recommending to expand the current indication for AYVAKYT® …
Latest content
Recruitment experts hired in search for new CGT Catapult chief
November 14, 2026
Envirogen secures place on NHS Scotland reverse osmosis framework
November 13, 2026
